Skip to main content

AIM ImmunoTech Inc.

For the period ended Oct 29, 2025. Filed Oct 29, 2025.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Oct 29, 2025 · Filed Oct 29, 2025

AIM$0.16+1.9%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Notes:

(1)All option awards were valued using the Black-Scholes method. The options for 2024 were waived.
(2)For Named Executive Officers, who are also Directors that receive compensation for their services as a Director, the Salary/Fees and Option Awards columns include compensation that was received by them for their role as a member of the Board of Directors. As is required by Regulation S-K, Item 402(c), compensation for services as a Director have been reported within the “Summary Compensation Table” (above) for fiscal years of 2024 and 2023 as well as reported separately in the “Compensation of Directors” section (see below) for calendar year 2024.

Pursuant to his current employment agreement, Mr. Equels is entitled to 3% of the “Gross Proceeds” (as defined in the employment agreement) for “significant events” (as described in the employment agreement) There were no payments during 2024 and 2023.

Pursuant to his current employment agreement, Mr. Rodino is entitled to 1% of the “Gross Proceeds” (as defined in the employment agreement) for “significant events” (as described in the employment agreement) There were no payments during 2024 and 2023.

As part of our cash conservation strategy, we issued common stock as a substitute for cash salaries to certain Named Executive Officers. For the year ended December 31, 2024, stock issued as payroll totaled $250,000, which is included in the overall equity-based compensation expense. There was no stock issued as payroll for the year ended December 31, 2023.

(3)Mr. Equels’ All Other Compensations consists of:
20242023
Life & Disability Insurance$41,073$41,073
Healthcare Insurance26,61924,316
Car Expenses/Allowance18,00018,000
401(k) Matching Funds20,70019,800
Total$106,392$103,189
(4)Mr. Dickey’s All Other Compensations consists of:
20242023
Life & Disability Insurance$—$—
Healthcare Insurance——
Car Expenses/Allowance——
401(k) Matching Funds——
Total$—$—
(5)Mr. Rodino’s All Other Compensations consists of:
20242023
Life & Disability Insurance$2,524$2,524
Healthcare Insurance25,39223,216
Car Expenses/Allowance14,40014,400
401(k) Matching Funds20,70019,800
Total$63,016$59,940
(6)All bonus compensation for 2023 was deferred to 2024 and subsequently paid in 2024. In last year’s table, Mr. Equels’ $350,000 bonus was not included for 2023 because it was accrued and not paid until 2024. This was disclosed in the footnotes to the table. As it was earned in 2023, it is now reported in 2023. The executive officers voluntarily waived all 2024 bonus compensation in support of the company’s cash conservation efforts.
Outstanding Equity Awards at Fiscal Year End · Option Awards · Stock Awards
NameNumber of Securities Underlying Unexercised Options (#) ExercisableNumber of Securities Underlying Unexercised Options (#) UnexercisableEquity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)Options Exercise Price ($)Option Expiration DateNumber of Shares or Units of Stock that Have Not Vested (#)Market Value of Shares or Units of Stock that Have Not Vested ($)Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that Have Not Vested (#)Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights that Have Not Vested ($)
Thomas K. Equels6——13,2006/8/2025————
President and Chief6——7,3926/8/2026————
Executive Officer68——2,4646/8/2027————
3——2,1566/15/2027————
3——2,1566/30/2027————
4——2,1127/15/2027————
5——1,8487/31/2027————
5——1,8048/15/2027————
6——1,5848/31/2027————
84——1,6282/13/2028————
28——1,6724/12/2028————
68——1,3205/16/2028————
57——1,3205/16/2028————
37——1,3647/18/2028————
65——96810/17/2028————
97——9681/28/2029————
3000——3078/12/2030————
3000——19611/11/2030————
3000——17111/11/2031————
3000——4111/30/2032————
3000——4711/30/2033————
Total15,542——————
Robert Dickey IV500——7003/03/2032————
Chief Financial Officer
Total500——————
Peter Rodino3——6,8656/21/2026————
COO, General Counsel and Secretary2——2,1566/15/2027————
2——2,1566/30/2027————
2——2,1127/15/2027————
2——1,8487/31/2027————
2——1,8048/15/2027————
3——1,5848/31/2027————
39——1,6282/13/2028————
23——1,6724/12/2028————
27——1,3205/16/2028————
17——1,3647/18/2028————
30——96810/17/2028————
45——9681/28/2029————
750——18512/9/2030————
1,000——14411/30/2031————
500——7003/03/2032————
1,000——4111/30/2032————
1,000——4711/30/2033————
Total4,447——————
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.